| Literature DB >> 31480225 |
Barbara E Cormack1,2, Jane E Harding2, Steven P Miller3,4, Frank H Bloomfield5,6.
Abstract
Extremely preterm babies are at increased risk of less than optimal neurodevelopment compared with their term-born counterparts. Optimising nutrition is a promising avenue to mitigate the adverse neurodevelopmental consequences of preterm birth. In this narrative review, we summarize current knowledge on how nutrition, and in particular, protein intake, affects neurodevelopment in extremely preterm babies. Observational studies consistently report that higher intravenous and enteral protein intakes are associated with improved growth and possibly neurodevelopment, but differences in methodologies and combinations of intravenous and enteral nutrition strategies make it difficult to determine the effects of each intervention. Unfortunately, there are few randomized controlled trials of nutrition in this population conducted to determine neurodevelopmental outcomes. Substantial variation in reporting of trials, both of nutritional intakes and of outcomes, limits conclusions from meta-analyses. Future studies to determine the effects of nutritional intakes in extremely preterm babies need to be adequately powered to assess neurodevelopmental outcomes separately in boys and girls, and designed to address the many potential confounders which may have clouded research findings to date. The development of minimal reporting sets and core outcome sets for nutrition research will aid future meta-analyses.Entities:
Keywords: amino acid; brain; extremely low birthweight; follow up; gestational age; growth; infant; newborn; nutrition; nutrition disorders/etiology; parenteral nutrition; premature; preterm
Mesh:
Year: 2019 PMID: 31480225 PMCID: PMC6770288 DOI: 10.3390/nu11092029
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Changes in neurodevelopmental outcomes for extremely preterm babies in 2008–2018.
Figure 2Nutrients needed for normal brain development.
Figure 3Effects of nutrient deficiency during brain development.
Randomised trials of interventions aiming for approximately 3 vs. 4 g·kg−1·d−1 IVN protein in the first week after birth.
| First Author Participants |
| Protein Intake Control Group g·kg−1·day−1 * | Protein Intake Intervention Group | Amino Acid Solution | Primary Outcome | Outcomes, Conclusions and Other Details |
|---|---|---|---|---|---|---|
| Tan <29 weeks | 114 | ~2.3 | 2.6 | Not specified | Head growth at 36 weeks | No difference in total brain volume on MRI at 40 weeks. Follow up rate 64% at 9 months. MDI and PDI correlated significantly with energy deficit at 28 days of age. Bayley II assessor not blinded to group allocation. |
| Blanco <1000 g | 32 | 2.9 | 3.7 (day 7) | Aminosyn | Mean serum potassium during first 3 days | Follow up rate 63% at 2 years. Bayley II PDI scores similar, but lower MDI score at 18 months in the high AA group. No difference at 24 months. No differences in cerebral palsy, blindness or early childhood intervention between groups at any age. More babies ≤24 weeks’ gestation allocated to higher protein group. |
| Burattini | 114 | ~2.5 | ~3.0 | TrophAmine | Weight and weight <10th centile at 36 weeks | Follow up rate 87% at 2 years. No difference in Bayley III scores. Caregivers aware of group allocation. |
| Morgan (SCAMP) | 150 | 2.4 week 1 | 2.8 | Vaminolact | Change in HC at 28 days postnatal age and 36 weeks | Follow up rate 62%. No difference in Bayley III assessments at 2 to 3.5 years. High protein group had higher HC z-score at 36 weeks (difference 0.40 95% CI 0.005–0.79, |
| Vlaardingerbroek <1500 g Netherlands [ | 103 | 2.4 + 1.4 g lipid on day 2 or 2.4 + 2–3 g lipid from birth | 3.6 | Primène | Composite outcome of death or major disability at 2 years | Follow-up rate 92%. No difference in Bayley III assessments and incidence of major disability between groups at 2 years. At 6 weeks, weight and HC z-scores significantly higher in high protein group. Addition of lipids and extra protein increased the amount of phenylalanine used for protein synthesis. |
| Uthaya (NEON) | 133 | 1.7 to 2.7 | 3.6 from day 1 | Vaminolact | Lean body mass | Follow up rate 79%. No significant differences for brain volume. HC at term-equivalent age was smaller in the high protein group (mean difference –0.8 cm, 95% CI–1.5 to–0.1 cm; |
| Bellagamba | 160 | ~2.5 | ~3.5 | TrophAmine | Weight gain from birth to 1800 g | Follow-up rate >90%. No differences in Bayley III scores at 2 years. Neonatologists not blinded to group allocation. IVN + enteral intervention. Difference in protein intakes between groups reached 1 g·kg−1·day−1 on day 4 |
| Balakrishnan | 168 | day 1–2 | 3 | Premasol | Bayley III at 18–24 months CGA | Follow-up rate 78%. No differences in Bayley III scores at 18–24 months. Largest study to date, single centre. Achieved at least 1 g·kg−1·day−1 difference in protein intakes between groups but for only first 3 days |
Trials are listed in chronological order of publication. Ages are post-menstrual age until term-equivalent and then corrected age unless otherwise specified. * Mean actual total protein intake, AA amino acid, CGA corrected gestational age, CI confidence interval, HC head circumference, MDI Motor Development Index, MRI magnetic resonance imaging, PDI Psychomotor Development Index.